BOLT · Bolt Biotherapeutics, Inc.

Summary

Bolt Biotherapeutics, Inc. reported fourth quarter and full-year 2025 financial results, including collaboration revenue of $2.5 million and $7.7 million, respectively, R&D expenses of $5.0 million and $28.5 million, and a cash balance of $31.8 million as of December 31, 2025, expected to fund operations into 2027. The company provided a business update on BDC-4182 Phase 1 trial with initial data expected in 3Q 2026.

Key takeaways

• Event Type: Earnings Release (Items: 2.02)